The Tumor-on-Chip: Recent Advances in the Development of Microfluidic Systems to Recapitulate the Physiology of Solid Tumors
Open accessThe DOI matches its Crossref record; 229 of the 231 references it cites were found in a registry or an index; 136 of the 207 sources its claims cite were checked for support.
Abstract
The ideal in vitro recreation of the micro-tumor niche-although much needed for a better understanding of cancer etiology and development of better anticancer therapies-is highly challenging. Tumors are complex three-dimensional (3D) tissues that establish a dynamic cross-talk with the surrounding tissues through complex chemical signaling. An extensive body of experimental evidence has established that 3D culture systems more closely recapitulate the architecture and the physiology of human solid tumors when compared with traditional 2D systems. Moreover, conventional 3D culture systems fail to recreate the dynamics of the tumor niche. Tumor-on-chip systems, which are microfluidic devices that aim to recreate relevant features of the tumor physiology, have recently emerged as powerful tools in cancer research. In tumor-on-chip systems, the use of microfluidics adds another dimension of physiological mimicry by allowing a continuous feed of nutrients (and pharmaceutical compounds). Here, we discuss recently published literature related to the culture of solid tumor-like tissues in microfluidic systems (tumor-on-chip devices). Our aim is to provide the readers with an overview of the state of the art on this particular theme and to illustrate the toolbox available today for engineering tumor-like structures (and their environments) in microfluidic devices. The suitability of tumor-on-chip devices is increasing in many areas of cancer research, including the study of the physiology of solid tumors, the screening of novel anticancer pharmaceutical compounds before resourcing to animal models, and the development of personalized treatments. In the years to come, additive manufacturing (3D bioprinting and 3D printing), computational fluid dynamics, and medium- to high-throughput omics will become powerful enablers of a new wave of more sophisticated and effective tumor-on-chip devices.
Overview
CoChat Summary
## TL;DR
This is a tutorial review of tumor-on-chip systems for solid-tumor research, arguing that microfluidic 3D models better recapitulate tumor physiology and dynamics than traditional 2D culture and many animal or static 3D models. It surveys recent device architectures and applications, especially spheroid models, co-cultures with stromal/healthy cells, vascularized chips, drug screening, nanoparticle transport, and precision-medicine uses.
## Key findings
- The paper states that less than 10% of anticancer drugs entering clinical trials reach the market, motivating more predictive preclinical models.
- Tumor-on-chip systems are presented as better than 2D culture because they can incorporate 3D architecture, dynamic flow, nutrients, and pharmaceutical compounds, and as more controllable than animal models, which are described as time-, resource-, and expertise-intensive and not fully human-relevant.
- In a 48-h perfused mesothelioma spheroid chip, spheroid morphology stayed essentially unchanged, but perfused spheroids showed higher chemoresistance to cisplatin than static spheroids; the system used about 5000 cells per assay.
- Several examples reported quantitative treatment or transport effects, including 100 nm nanoparticles penetrating better than 200 nm particles, DOX at 10 and 100 µg/mL destroying an endothelial barrier in one co-culture model, vessels in breast tumor compartments being 2.62-fold more permeable to nanoparticles than healthy-tissue vessels, and vascularized HCT116 microtumors showing one-order-higher chemoresistance to oxaliplatin than 2D monolayers.
## Methods
- Design: Narrative/tutorial review organized by increasing model complexity: simple spheroids, spheroids in hydrogels, non-spheroid cancer–normal co-cultures, vascularized systems, and precision-medicine applications.
- Data/sample: The review focuses on recent literature from 2011 onward on solid-tumor microfluidic systems and cites multiple representative device studies and model systems.
- Analysis: Comparative synthesis of published examples, emphasizing device architecture, fabrication/materials, flow and pressure control, and reported biological readouts such as drug response, nanoparticle transport, cell invasion, and vascular permeability.
## Limitations
- The paper states that the complete recapitulation of the true nature and evolution of a malignant tumor in vitro is challenging, and that high-fidelity 3D emulation remains an aspiration.
- It states that microfluidic device fabrication still requires skill and experience, and that better biomaterials, 3D printing, CFD, and omics will be needed for more advanced systems.
- Evident from the text: this is a review, not an original experimental study, so its conclusions depend on the quality and scope of the cited literature rather than new primary data.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures
![Figure 1 Recapitulation of the tumor niche using tumor-on-chip systems with various degrees of sophistication. (a) The evolution of our cancer research tools—from 2D to 3D, and beyond—tumor-on-chip systems. Colored circles show the degree of fulfillment of different features. Green: fully fulfilled; Yellow: partially fulfilled; Red: poorly fulfilled; (b) Scheme of the tumor niche. Modified from Han et al., 2016 [19]. (c) Different types of tumor-on-chip systems: from simple spheroids in a microflow to vascularized and perfusable tumor microtissues [20,21,22,23,24,25,26,27,28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45,46,47,48,49,50,51,52,53,54,55,56,57,58,59,60,61,62,63,64,65,66,67,68,69,70,71,72].](https://figures.cochat.ai/paper-figures/c26bbf874804474397dc5dfe2bb673c9/the-tumor-on-chip-recent-advances-in-the-development-of-microfluidic-systems-to-figure-1.jpg)
![Figure 2 Architecture of tumor spheroids and their fabrication techniques. (a) Schematic representation of the 3D architecture of a tumor spheroid. Modified from Sant and Johnston 2017 [126]; (b) Fabrication of spheroids by the following scaffold-free methods: (i) hanging drop [122,127,128,129], (ii) liquid-overlay method [130,131,132,133,134,135,136], and (iii) force-driven method [129,132,137,138,139,140,141]; (c) Fabrication of spheroids by the following scaffold-based methods: (i) spheroids with a matrix-on top and embedded in a matrix [133,134,135], (ii) spheroids encapsulated within a molded matrix [142,143,144], and (iii) spheroids formed by suspending cancer cells within a liquid matrix and applying microfluidic-based strategies to form spheroids in droplets [119,145,146,147,148].](https://figures.cochat.ai/paper-figures/e54332efbd5643e0917a359371e47974/the-tumor-on-chip-recent-advances-in-the-development-of-microfluidic-systems-to-figure-2.jpg)
![Figure 3 Simple tumor-on-chip systems: a tumor spheroid continuously perfused within a microfluidic device. (a) Simple serpentine-shaped microfluidic system designed by Ruppen et al. [20], (i) designed to trap cancer cell agglomerates for fabrication of tumor spheroids. A simple hydraulic system enabled the trapping of cell agglomerates (scale bar: 10 μm) (ii) in small cavities. Once the upstream cavities were occupied by spheroids, flow was directed to downstream portions of the serpentine (scale bar: 500 μm) (iii) to favor new trapping events. (iv) Spheroids grew and matured in these cavities and were continuously exposed to anticancer compounds. Taken from reference [20]; (b) Microfluidic device developed by Huang et al. [21]: (i) general architecture, (ii) hydraulic testing, (iii) detail of the spheroid traps, and (iv) actual spheroid trapped in a holder as imaged in bright field. Schematic representation of the effect of (scale bar: 50 μm) (v) protein corona, and (vi) charge, on nanoparticle penetration into tumor spheroids. Taken from reference [21]; (c) Simple pump-independent (i) microfluidic system devised by Patra et al. [22] for continuous formation and perfusion of cancer spheroids (ii) contained within rectangular cavities located at the floor of the microfluidic circuit. (iii) Flow is driven simply by a pressure head induced by a difference in the height of the column of liquid (culture medium) between the inlet and the outlet reservoir. Taken from reference [22]; (d) Tumor-on-chip system developed by Chen et al. [177]: (i) Scheme of the physiological context aimed, (ii) and overall microfluidic architecture. (iii) 3D-render showing cancer cells retained within a horseshoe trap. Red and blue arrows indicate the flow fields within the system. (iv) Scheme of the architecture of the system (side view), (v) detail of the array of traps holding spheroids of consistent size, and (vi) size of spheroids after 14 days of culture. Scale bar: 200 μm. Taken from reference [177]; (e) The microfluidic system developed by Lim and Park [23] enables the exposure of cancer spheroids to anticancer drug gradients. (i) Scheme of the overall architecture of the device, (ii) detail of the cell-culture section, and (iii) close-up showing the geometry of each culture microwell. (iv) Experimental demonstration of the effective generation of gradients using injections of a fluorescent tracer. Taken from reference [23].](https://figures.cochat.ai/paper-figures/7970a8152adf491395a936fa18311833/the-tumor-on-chip-recent-advances-in-the-development-of-microfluidic-systems-to-figure-3.jpg)
![Figure 4 Tumor-on-chip in which a spheroid is embedded in a hydrogel. (a) Microfluidic system proposed by Albanese et al. [27]: (i) scheme of the optically accessible TOC, (ii) actual image of the spheroid within the microfluidic chamber (scale bar: 1000 μm). The tumor spheroid is lightly embedded in collagen. Scale bar: 100 μm. (iii) Interstitial volume exchange (residence time within a spheroid) as a function of the inlet flow rate (black squares); the corresponding interstitial flow rate is shown (red diamonds). (iv) Scheme and image of 40 nm PEG nanoparticles penetrating the spheroid and accumulating in the interstitial spaces (scale bar: 100 μm). (v) Larger nanoparticles (d = 110 nm) cannot penetrate the spheroid. Scale bar: 100 µm. (vi) Nanoparticle of different sizes [40 nm (red); 70 nm (blue); 110 (green), and 150 (blue)] exhibit different accumulation rates within spheroids. Nanoparticles were injected into the chamber at 50 mL/h; (b) The tumor on chip designed by Kwak et al. [28] aimed to recapitulate (i) the dynamics induced by the pressure gradient between the capillary and the lymphatic nets. (ii) Scheme (scale bar: 300 μm) and (iii) actual microdevice: cancer spheroids (indicated by arrows) develop within collagen in the central compartment by day 3. These spheroids, like actual tumors, express (iv) E-cadherin and (v) collagen IV. Scale bar: 50 µm. This system enables studies of accumulation of nanoparticles within tumors. (vi) Concentration of 100 nm particles at different distances of the capillary boundary (vii) Accumulation of nanoparticles as a function of matrix stiffness, (viii) interstitial pressure, and (ix) particles size. Taken from reference [28]; (c) TOC devised by Piotrowsky-Daspit [30] to study the effect of intra-tumor interstitial pressure on tumor invasiveness. (i) Schematic representation of the device; (ii) Micrographs showing an E-cadherin-GFP aggregate under a condition where the pressure gradient favors invasiveness (higher pressure at the tumor core). Modified from Piotrowsky-Daspit [30].](https://figures.cochat.ai/paper-figures/949525e8367d4789b57e35a88a0a5f66/the-tumor-on-chip-recent-advances-in-the-development-of-microfluidic-systems-to-figure-4.jpg)
![Figure 5 Tumor-on-chip (TOC) systems in which cancerous and normal microtissues share an interface. (a) Crosstalk between cancer cells and fibroblasts in a Y-shaped TOC: (i) scheme and (ii) actual device. (iii) Human mammary fibroblasts (HMF) and breast cancer (MCF10-DCIS) cells establish a cross-talk at the interface between the cancerous and normal microtissue sections. Scale bar: 30 µm. (iv) Circularity, roundness, and aspect ratio (AR) of MCF10-DCIS cancer cells as a function of their distance from the interface. (v) Image analysis characterization of invasiveness. Taken from reference [33]; (b) On-chip activation of stromal tissue by crosstalk with cancerous tissue [35]: (i) schematic representation of the device and (ii) actual micrographs of normal cells (expressing GFP) and cancer cells (expressing RFP). Scale bar: 100 μm. (iii) Time sequence showing cancer cell migration and invasion. Scale bars: 100 μm; (c) TOC system that recapitulates early stage breast cancer: (i) tumor-niche aimed. (ii) Schematic representation of the TOC system. (iii) Cytotoxicity against cancerous DCIS spheroids and normal epithelial cells at different feeding conditions: continuous administration of Paclitaxel through the lower channel (open triangles), batch administration of paclitaxel on normal epithelial cells (open circles), and negative control (squares). (iv) Change in the projected area of a DCIS spheroid treated with paclitaxel in the TOC (white bars) and untreated (black bars; ** p < 0.05) (v) Micrographs of DCIS spheroids at day 0, after three days of culture, and after three days of paclitaxel treatment. Scale bars: 100 μm; (d) TOC by Ayuso et al. [36] to recapitulate hypoxia and nutrient gradients within cancerous tissue: (i) schematic representation and (ii) actual device. Scale bar: 1 cm. (iii) Evolution of the cancer cell viability profiles, and (iv-v) hypoxia levels within the device. Scale bar: 400 μm Taken from reference [36].](https://figures.cochat.ai/paper-figures/a5f48478b57c401495df89942ff126f5/the-tumor-on-chip-recent-advances-in-the-development-of-microfluidic-systems-to-figure-5.jpg)
![Figure 6 Tumor-on-chip (TOC) systems that consider spheroids embedded in non-cancerous cell-laden-hydrogels. (a) Chemotaxis-driven assembly of endothelial barrier in a TOC platform [50]. Brightfield images of MCF7 spheroids co-cultured with human umbilical vein endothelial cells (HUVECs) (i) immediately after encapsulation, (ii) after three, and (iii) five days of culture. Scale bars: 200 μm. (iv) Evolution of HUVEC densities within different GelMA hydrogel zones 1 through 5 (zones are indicated on the oval inset). Zones are indicated within the inset. (v) Spheroid size as a function of culture time. Size was quantified as the projected area of the spheroid and normalized to its size at day 0; (*) and (**) indicate statistically significant differences of p < 0.05 and 0.01, respectively in a pairwise t-test. (vi) HUVECs and MCF7 spheroids (as observed in bright field) five (D5) and eight days (D8) after doxorubicin (DOX) treatment. Red arrows indicate the presence (or absence) of endothelial barrier. Scale Bar: 200 μm. (vii) MCF7 spheroid size after treatment with increasing doses of DOX. The spheroid area was normalized with respect to that of untreated spheroids. Significant differences are indicated by (*, **): p < 0.05 and 0.01, respectively (pair wise t-test). Taken from reference [50]; (b) TOC developed by Jeong et al. [51] to study the crosstalk and mutual activation between fibroblasts and cancer cells: (i) schematic of the device, (ii) and (iii) successive close-ups on the channel section, (iv) detail of the cell culture channel, and (iv) comparison of migration distances of fibroblasts in the direction of the cancerous region (blue) and the non-cancerous region (gray). (vi) Micrographs of cancer spheroids treated with different doses of DOX in monoculture and co-culture conditions. Scale bars: 50 μm. (vii) Evaluation of DOX efficacy in co-culture and monoculture conditions in this TOC. Significant differences are indicated by (*): p < 0.05. Taken from reference [51]; (c) TOC developed by Aref et al. [48], to model immune checkpoint blockade. (i) A real tumor is subjected to dissociation (mechanical and enzymatic) to yield dissociated tumor tissue (spheroids, cell agglomerates and single cells); (ii) schematic of Aref’s TOC; (iii) spheroid stained to reveal the presence of calcein AM (green); CD8 T cells (red); tumor cells (EpCAM; purple); and all nucleated cells (Hoechst; blue). Scale bars: 20 μm. (iv) Cell viability, and (v) cytokine expression profile over time in spheroids derived from patients and treated with different immunotherapies: α-PD-1: pembrolizumab, 250 μg mL−1); α -CTLA-4: (ipilimumab, 50 μg mL−1); or a combination. Taken from reference [48]. (d) TOC proposed by Bruce et al. [49] to recreate a bone marrow microenvironment and study acute lymphoblastic leukemia (ALL): (i) schematic representation, (ii) actual image, (iii) and detail of the post array within the device. (iv–vii) Confocal images of co-cultures of SUP-B15 (yellow arrows) and BMSC cells (white arrows) in (iv) 2D static, (v) 3D static, and (scale bars: 500 μm and 100 μm) (vi) 3D dynamic models. Proliferating cell nuclei were stained with Ki67 (green). Actin filaments were stained with phalloidin (red). Cell nuclei were stained with DAPI (blue). Scale bars: 20 μm. (vii) Chemoresistance of tumor cells to Ara-C among tri-culture or monoculture systems, in 2D versus 3D culture, and exposed (or not) to interstitial flow. (+) and (*) indicate significant difference between groups of p < 0.1, and p < 0.05, respectively. Taken from reference [49].](https://figures.cochat.ai/paper-figures/bf26efaa736246e18e74849343e0410f/the-tumor-on-chip-recent-advances-in-the-development-of-microfluidic-systems-to-figure-6.jpg)
![Figure 7 Vascularized tumor-on-chip (TOC) systems. (a) A gelatin and hyaluronic acid (HA) construct, built in a PDMS device, traversed by an endothelialized microchannel. Taken from reference [54]; (b) TOC devised by Ozkan et al. [55]. (i) Schematic representation of a breast tumor microenvironment connected to a healthy liver niche. (ii) Close-up view of the TOC system. Confocal images show GFP-breast cancer cells (green) and particles circulating inside the vascular channel (red) and FITC-anti-albumin immunostained healthy liver cells (green) and particles circulating inside the vascular channel (red). Scale bar: 500 µm. (iii) CFD simulation showing the cross-sectional shear stress profiles in tumor and healthy vessels. Taken from reference [55]; (c) TOC by Shirure et al. [56]. (i) Schematic representation of the device, and (ii) confocal slice of the microvascular network (green) fabricated within the TOC central chamber and perfused with fluorescently labeled dextran (orange). Scale bar: 50 µm. Taken from reference [56]; (d) Bottom-up engineering of vascularized tumor models proposed in Agarwal et al. [57]. (i) Schematic representation of the strategy. (ii) Comparison of the effect of docetaxel, expressed as IC50, for three different microtumor models: 2D (black), a-vascular 3D (blue) and vascularized 3D (red) models; (*) indicate statistically significant difference of p < 0.05 when 3D vascularized models are compared to 2D culture model, and (#) significant differences of p < 0.05 when 3D vascularized models are compared with 2D and 3D avascular culture models. Taken from reference [57]. (e) Vascularized tumor-on-chip developed by Sobrino et al. [58]. (i) Scheme of the microfluidic device: a PDMS microfluidic chip composed of an array of three tissue chambers, each connected to two straight channels mimicking an arteriole (line of higher pressure) and the venule (line of lower pressure). Channels were also connected to the medium inlets and outlets. A hydrostatic pressure differential of 10 mm H2O was established to enable flow across the microfluidic channel, while a pressure gradient of 5 mm H2O was set across the tissue chambers to favor transport across the hydrogel. (ii) A human-endothelial cell vasculature net was fabricated within diamond-shaped tissue chambers containing EC-like matrix. Remarkably, the development of vasculature in these tissue chambers occurred spontaneously by self-assembly of EC cells initially seeded within the channels and the tissue chamber at day zero. Endothelial cells were continuously transduced with mCherry for easy visualization of the network (iii) Experiments of continuous perfusion of Dextran X show that the vascular network is practically leak-free after several days. (iv) Growth of tumors, fabricated by a spheroid formation method assisted by thrombin, seeded within the vasculature network models after 6, 8, 10, and 12 days of culture at continuous perfusion. (v) Different drugs were tested in this tumor-on-chip system; (vi and vii) the model correctly discriminates between drugs that target the tumor-vasculature formation capabilities and those that target the tumor. Scale bars: 50 µm. Taken from reference [58].](https://figures.cochat.ai/paper-figures/c1fbb9d2d8a445028c0bcc79d8928c86/the-tumor-on-chip-recent-advances-in-the-development-of-microfluidic-systems-to-figure-7.jpg)
![Figure 8 Application scenarios for tumor-on-chip systems. (a) Fundamental studies [30,31,33,35,36,41,43,44,45,48,50,51,53,54,55,56,60,62,64,65,66,67,68,70,71,72,73,80,85,105,186,187,188,189,190,191,192,193]; (b) Pharmacological screening and testing [21,22,23,27,28,29,32,43,47,50,55,56,57,58,59,63,64,165,177,194]; and (c) personalized/precision medicine strategies [24,37,42,56,69,104,195,196,197,198].](https://figures.cochat.ai/paper-figures/311ce3dde0064969ab8ec026c7090291/the-tumor-on-chip-recent-advances-in-the-development-of-microfluidic-systems-to-figure-8.jpg)
Verification
Claims the paper makes
103 Valid · 4 Not valid · 30 Not checked · 12 Own results and interpretations
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“For example, when Pbase was higher than Ptip, an invasive phenotype was favored”
§ The Tumor-on-Chip: Recent Advances in the Development of Microfluidic Systems to Recapitulate the Physiology of Solid Tumors > 5. Tumor-on-Chip Examples > 5.2. Spheroids in a Hydrogel Matrix
What the sources say
- Disputedcites [30] Piotrowski-Daspit A.S. Tien J. Nelson C.M. Interstitial fluid pressure regulates collective invasion in engineered human breast tumors via Snail, vimentin, and Transition to invasion Integr. Biol. 2016 8 319 331 10.1039/c5ib00282f PMC4792648 26853861 sourceExperimental — accuracy not yet measured
The Results section reports the opposite: when Pbase>Ptip, none of 51 aggregates developed invasions. Invasion was promoted when Pbase<Ptip, with 50% of aggregates developing invasions. Page numbers were not provided in the supplied passages. (LLM, conf=0.90)
Checked by a reasoning model — may be wrong.
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“The penetration of NPs into the tissue was mainly influenced by their diameter (Figure 4a-iv–vi) and NP transport was predominantly dispersion-limited.”
§ The Tumor-on-Chip: Recent Advances in the Development of Microfluidic Systems to Recapitulate the Physiology of Solid Tumors > 5. Tumor-on-Chip Examples > 5.2. Spheroids in a Hydrogel Matrix
What the sources say
- Disputedcites [27] Albanese A. Lam A.K. Sykes E.A. Rocheleau J.V. Chan W.C.W. Tumour-on-a-chip provides an optical window into nanoparticle tissue transport Nat. Commun. 2013 4 2718 10.1038/ncomms3718 24177351 PMC3947376 sourceExperimental — accuracy not yet measured
The Results section (“Effect of flow rate on tissue accumulation”) says nanoparticles diffuse into spheroid tissue after accumulating at its surface; increased flow did not increase penetration depth. The claim says transport was predominantly dispersion-limited, whereas the paper describes diffusion as the mechanism of penetration. Its separate finding that diameter limits penetration is supported by the Results (“Effect of nanoparticle size on tissue accumulation”). (LLM, conf=0.88)
Checked by a reasoning model — may be wrong.
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“Indeed, the 3D static and microfluidic models demonstrated coordinated cell-cell and cell-matrix interactions that were not detectable in the 2D static model.”
§ The Tumor-on-Chip: Recent Advances in the Development of Microfluidic Systems to Recapitulate the Physiology of Solid Tumors > 5. Tumor-on-Chip Examples > 5.4. Spheroids Surrounded by “Healthy” Tissues In some instances, tumor spheroids have been embedded in hydrogels containing normal (i.e., non-cancerous cells) within microfluidic chambers. For example, Aung et al. [50] developed a tumorous microtissue encapsulated by an endothelial barrier composed of HUVECs. The authors mixed breast cancer spheroids (MCF-7) into a suspension of HUVECs (~50 spheroids into 5 mL of a HUVEC suspension containing 0.4 × 105 cells/mL). This mix was centrifuged, and the pellet was suspended in 100 µL of 10% gelatin methacryloyl (GelMA); this new mixture was then loaded into thin microfluidic devices. Using a microscope, the authors located areas where cancer spheroids were surrounded by HUVECs and photocrosslinked these locations, flushing out the rest of the non-crosslinked hydrogel. This operation resulted in a hydrogel micro-cosmos containing spheroids surrounded by HUVEC cells. Over time, the HUVECs chemotactically migrated from the bulk of the hydrogel towards its perimeter and spontaneously developed an endothelial barrier around the GelMA construct (Figure 6a-i–iii). As a result, starting from homogeneity, the HUVEC density varied in different areas within the constructs over time (Figure 6a-iv). The size of the tumor spheroids, as determined by their projected area, also increased over time (Figure 6a-v). Thus, this tumor-on-chip produces tumor spheroids within a semisynthetic extracellular matrix embedded in a cell-monolayer endothelial barrier conformed by tight cell-cell E-cadherin junctions and encompassing the entire length of the GelMA hydrogel. This simple and smart platform was also used to evaluate the effect of DOX (Figure 6a-vi,vii). After 5 days of cultivation, they administered different doses of DOX (1, 10 and 100 µg/mL) for 3 days. Figure 6a-vi shows bright-field images of the HUVEC-MCF7 constructs before (top row) and 3 days after (bottom row) DOX treatment. Red arrows indicate the endothelial barrier. At concentrations of 10 and 100 μg/mL, DOX destroyed the endothelial barrier, decreased the size of spheroids, and caused a darkening of the MCF7 spheroids (Figure 6a-vii). Jeong et al. developed a tumor-on-chip to investigate the 3D interplay between cancer cells and fibroblasts (Figure 6b) [51]. This tumor-on-chip system consisted of four units; each unit comprised seven channels, each one 1000 μm wide and 190 μm deep (Figure 6b-i–iv). Channels 2, 6, and 4 were designated for non-cancer or cancer cell culture, and channels 1, 3, 5, and 7 were used for medium filling (Figure 6b-iii). The device was designed for intermittent feeding and the cell culture medium was changed every day. A collagen I solution (2 mg/mL) was mixed with the cells before being loaded into the device channels. Mono- and co-cultures of HT29 cancer cells and normal fibroblasts (CCD-18Co) were performed (Figure 6b-v) and, in some experiments, naïve collagen I (without cells) was loaded in the different channels of the device. A crosstalk between the cancer cells and fibroblasts was observed. After 5 days, the HT-29 cells formed viable spheroids and their growth was stimulated by co-culture with fibroblasts (Figure 6b-v). Increased expression of α-SMA and enhanced migration activity suggested fibroblast activation. The authors also observed changes in the expression of intracellular proteins related to angiogenesis and apoptosis. For instance, CD26, GM-CSF, SerpinE1, TIMP-1, HB-EGF, TSP-1, and GDNF were up-regulated and phospho-p53 (S15), phospho-p53 (S46), phospho-p53 (S392), pro-caspase-3, and cytochrome C were down-regulated in the tumor spheroids in co-culture. The spheroids co-cultured with fibroblasts exhibited increased expression of fibronectin, along with reduced expression of Ki-67. The effects of DOX and paclitaxel were also evaluated in this platform. Co-cultured spheroids also exhibited lower levels of DOX uptake and reduced sensitivity to paclitaxel (Figure 6b-vii). This 3D co-culture platform enabled the study of tumor microenvironment factors related to the epithelial-mesenchymal transition process, fibroblast activation, and drug resistance. Aref et al. conducted experiments in a commercial DAX-1 microfluidic system (Aim Biotech) in which patient-derived spheroids (PDOSTS) were cultured in contact with immune system cells to recreate the tumor immune microenvironment and screen the response of tumors to immunotherapy (therapies based on antibodies) [48]. Tumor biopsies from patients were mechanically and enzymatically dissociated to yield spheroids, cell agglomerates, and single cells (Figure 6c-i). The spheroids were separated for culture in the DAX-1 microfluidic device (Figure 6b). The DAX-1 chip was composed of three microfluidic chambers—a central gel channel surrounded by two channels for media circulation (Figure 6c-ii). The PDOSTS spheroids (40–100 μm in diameter) were embedded in collagen type I hydrogels in the central chamber and cultured. In the side channels, medium with or without monoclonal antibodies was circulated. The authors demonstrated the presence of autologous tumor-infiltrating immune cells (CD8-T) (Figure 6c-iii). Treatment with an anti-PD-1 antibody showed cancer cell death mediated by CD8 T-cells. Analysis of cytokines (Figure 6c-iv,v) revealed a natural evolution of cytokine and growth factor secretion over time (e.g., IL-8 VEGF, IL-12, CCL4). This study demonstrated that patient-derived tumor spheroids retain lymphoid and myeloid subsets of immune cells and that those cell populations could be further cultured in microfluidic chips. Bruce et al. studied acute lymphoblastic leukemia (ALL) in a 3D microfluidic system (Figure 6d) [49]. The device consisted of four perfusion microchannels. Chip dimensions were set considering the nutrient diffusion limits (i.e., relevant diffusional length scales) and aimed to recreate the interplay between the different cell types involved in ALL (Figure 6d-i,ii). Cell loading and culture medium feeding was performed through two ports (“cell in” and “media in”) placed at the inlet side of the device. SUP-B15 leukemic cells were cultured in the presence or absence of human bone marrow stromal cells (BMSCs) and human osteoblasts (HOBs). Cells were suspended in medium with 88% collagen type I—a concentration that is consistent with the stiffness of bone marrow (< 300 Pa). After collagen I gelation, culture medium was fed through the inlet and into the microchannels. Velocity profiles within the microchannels, set to be similar to that in the interstitial space of the bone marrow, were maintained at 0.27 ± 0.18 μm/s. Cell culture was performed in 2D static, 3D static, and 3D microfluidic models (Figure 6d-iv–vi), and significant differences in cell morphology and expression were found. The authors used this microfluidic platform to evaluate cell-cell and cell-matrix interplay in a controlled microenvironment that recapitulated physiological ranges of critical dynamical variables. Indeed, the 3D static and microfluidic models demonstrated coordinated cell-cell and cell-matrix interactions that were not detectable in the 2D static model. The 3D platform proved to be a more accurate bone marrow niche model, where different cells in culture (leukemic cells, human bone marrow stromal cells, and human osteoblasts) could interact in a dynamic fashion. In addition, chemoresistance studies were carried out by exposing 2D and 3D cultures to cytarabine (Ara-C), and the bone marrow microenvironment was found to have a protective role in cancer cell survival during treatment. Moreover, a lower chemotherapeutic sensitivity of leukemic cells was observed in the 3D tri-culture models than in the 2D models (Figure 6d-vii,viii). The 3D microfluidic model developed in this work is a suitable in vitro option for the study of tumor cell biology in the bone marrow niche (i.e., the space where the leukemic disease is initiated) and the site of metastatic malignancies characterized by high anticancer drug resistance.
What the sources say
- Disputedcites [49] Bruce A. Evans R. Mezan R. Shi L. Moses B.S. Martin K.H. Gibson L.F. Yang Y. Three-Dimensional Microfluidic Tri-Culture Model of the Bone Marrow Microenvironment for Study of Acute Lymphoblastic Leukemia PLoS ONE 2015 10 e0140506; 10.1371/journal.pone.0140506 26488876 PMC4619215 sourceExperimental — accuracy not yet measured
In Results and Discussion, “Cell-Cell Interactions” (page not supplied), the paper says direct cell-cell interactions were visible in the 2-D static model, contrary to the claim that they were not detectable there. It also says the 3-D static model lacked interaction without dynamic stresses. The paper favors the 3-D microfluidic model as a more authentic niche, but not the claimed contrast across all three models. (LLM, conf=0.87)
Checked by a reasoning model — may be wrong.
boostedstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
Every source the paper cites for this claim was checked and supports it.
In the paper
“In addition to their remarkable internal heterogeneity, the tumor stromal tissues (i.e., the tissues surrounding the tumor), act as a dynamic source (and reservoir) of various cytokines and growth factors that influence tumor progression and pharmacological responses [19].”
§ The Tumor-on-Chip: Recent Advances in the Development of Microfluidic Systems to Recapitulate the Physiology of Solid Tumors > 2. The Tumor Niche
What the sources say
- Supportedcites [19] Han B. Qu C. Park K. Konieczny S.F. Korc M. Recapitulation of complex transport and action of drugs at the tumor microenvironment using tumor-microenvironment-on-chip Cancer Lett. 2016 380 319 329 10.1016/j.canlet.2015.12.003 26688098 PMC4902790 source
The Introduction describes stromal tissue as a repository for growth factors and cytokines that influence tumor growth and drug response. Section 2 also describes stromal-associated cells producing cytokines and links the resulting chemical environment to tumor progression and therapeutic resistance. Page numbers are not provided in our copy. (LLM, conf=0.94)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Recently, organ-on-chip systems—microphysiological systems that combine the use of microfluidics, tissue engineering, and microfabrication tools—have shown promise sustaining functional microtissues for relatively extended timeframes [9,10,11,12].”
§ The Tumor-on-Chip: Recent Advances in the Development of Microfluidic Systems to Recapitulate the Physiology of Solid Tumors > 1. Introduction
What the sources say
- Not checked — no full text of the sourcecites [9] Zheng F. Fu F. Cheng Y. Wang C. Zhao Y. Gu Z. Organ-on-a-Chip Systems: Microengineering to Biomimic Living Systems Small 2016 12 2253 2282 10.1002/smll.201503208 26901595 source
- Partly supportedcites [10] Esch E.W. Bahinski A. Huh D. Organs-on-chips at the frontiers of drug discovery Nat. Rev. Drug Discov. 2015 14 248 260 10.1038/nrd4539 25792263 PMC4826389 sourceExperimental — accuracy not yet measured
The ‘Comparison with conventional models’ section says organs-on-chips can reconstitute organ-level physiological functions, supporting the functional-microtissue part of the claim. But the passages do not establish that this function is sustained for relatively extended periods; ‘Current challenges and limitations’ instead describes long-term culture as a major challenge. Page numbers are not available in our copy. (LLM, conf=0.84)
- Supportedcites [11] Trujillo-de Santiago G. Lobo-Zegers M.J. Montes-Fonseca S.L. Zhang Y.S. Alvarez M.M. Gut-microbiota-on-a-chip: An enabling field for physiological research Microphysiol. Syst. 2018 2 10.21037/mps.2018.09.01 PMC8096182 33954286 source
The “Microbiota-related studies in gut-on-chip systems” section (page unavailable) describes Caco-2 cells cultured for one week in a gut-on-chip model and reports tests of epithelial barrier integrity. It also reports that a Caco-2 monolayer remained viable during 48 hours of exposure to bacterial biofilm products, supporting the hedged claim that such systems show promise for sustaining functional tissue models over extended periods. (LLM, conf=0.85)
- Not checked — no full text of the sourcecites [12] Zhang B. Radisic M. Organ-on-a-chip devices advance to market Lab Chip 2017 17 2395 2420 10.1039/C6LC01554A 28617487 source
plainstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
100 more claims · 74 with their cited sources checked
Create a free account to see all 149 claims and to verify the 11 references still open.
- It may state two separate claims as one. 33
- Probably not a substantial claim. 10
- The quote only partly states this claim. 2
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“These systems enable continuous delivery of oxygen, nutrients, and therapeutic agents while introducing shear stress and directional mass transport, thereby allowing the investigation of flow-regulated processes within a tumor-relevant architecture [224,225,226,227,228].”
From Modeling Tumor Microenvironment Complexity In Vitro: Spheroids as Physiologically Relevant Tumor Models and Strategies for Their Analysis (2025) · cites this paper as [225]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ The Tumor-on-Chip: Recent Advances in the Development of Microfluidic Systems to Recapitulate the Physiology of Solid Tumors > 5. Tumor-on-Chip Examples > 5.3. Non-Spheroid Models where 3D Cancer Tissues are in Contact with Non-Cancerous Tissues
“The HMFs and MCF10-DCIS cells established a crosstalk at the interface between the cancerous and normal microtissue sections.”
§ The Tumor-on-Chip: Recent Advances in the Development of Microfluidic Systems to Recapitulate the Physiology of Solid Tumors > 5. Tumor-on-Chip Examples > 5.3. Non-Spheroid Models where 3D Cancer Tissues are in Contact with Non-Cancerous Tissues
“The change in shape of MCF710-DCIS cells, and their ability to remodel the matrix, suggested the onset of a DCIS to IDS transition.”
Citations
Cites
Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21492 · Cited by 84,109 · cited 2×
“5 million will die from this disease, according to GLOBOCAN 2018 estimates [1].”
BackgroundStem cells, cancer, and cancer stem cells
Reya, T., Morrison, S. J., Clarke, M. F., & Weissman, I. L. (2001) · Nature · doi:10.1038/35102167 · Cited by 9,738 · cited 1×
“In the end, cancer is a genetic disorder [88,89].”
BackgroundAngiogenesis in cancer and other diseases
Carmeliet, P., & Jain, R. K. (2000) · Nature · doi:10.1038/35025220 · Cited by 9,070 · cited 2×
“Therefore, vascularization is another relevant aspect to consider when engineering a tumor local microenvironment [180,181].”
BackgroundVogelstein, B., Papadopoulos, N., Velculescu, V. E., Zhou, S., Diaz, L. A., & Kinzler, K. W. (2013) · Science · doi:10.1126/science.1235122 · Cited by 7,863 · cited 1×
“The nature of these mutations differs for each cancer [90] and in each individual [90–92].”
BackgroundMacrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm
Biswas, S. K., & Mantovani, A. (2010) · Nature Immunology · doi:10.1038/ni.1937 · Cited by 3,840
Synthesis, properties, and biomedical applications of gelatin methacryloyl (GelMA) hydrogels
Yue, K., Trujillo-de Santiago, G., Alvarez, M. M., Tamayol, A., Annabi, N., & Khademhosseini, A. (2015) · Biomaterials · doi:10.1016/j.biomaterials.2015.08.045 · Cited by 3,146 · cited 1×
“Several techniques also involve the use of semi-synthetic polymers, such as gelatin methacryloyl (GelMA) [166] based hydrogels [135,167], or self-assembling peptides, such as RADA16-I, Q11, and bQ13, that can form gels under specific conditions (e.”
BackgroundHoadley, K. A., Yau, C., Hinoue, T., Wolf, D. M., Lazar, A. J., Drill, E., Shen, R., Taylor, A. M., Cherniack, A. D., Thorsson, V., et al. (2018) · Cell · doi:10.1016/j.cell.2018.03.022 · Cited by 2,546
Ferlay, J., Colombet, M., Soerjomataram, I., Dyba, T., Randi, G., Bettio, M., Gavin, A., Visser, O., & Bray, F. (2018) · European Journal of Cancer · doi:10.1016/j.ejca.2018.07.005 · Cited by 2,478
The causes and consequences of genetic heterogeneity in cancer evolution
Burrell, R. A., McGranahan, N., Bartek, J., & Swanton, C. (2013) · Nature · doi:10.1038/nature12625 · Cited by 2,262
The role of hypoxia in cancer progression, angiogenesis, metastasis, and resistance to therapy
Muz, B., de la Puente, P., Azab, F., & Azab, A. K. (2015) · Hypoxia · doi:10.2147/hp.s93413 · Cited by 2,066 · cited 1×
“For instance, recently published literature discusses the role of the size of a tumor (and the associated hypoxia levels) on its aggressiveness [81–85] and on the efficacy of drug delivery to it [84,86,87].”
Background
Cited by
Nanomedicine in cancer therapy
Fan, D., Cao, Y., Cao, M., Wang, Y., Cao, Y., & Gong, T. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01536-y · Cited by 878
Organoid and Spheroid Tumor Models: Techniques and Applications
Gunti, S., Hoke, A. T. K., Vu, K. P., & London, N. R. (2021) · Cancers · doi:10.3390/cancers13040874 · Cited by 479
“However, a majority of these studies utilized cancer cell lines to co str ct s eroi s a o ly fe studies used patient-derived tumor tissue [74].”
BackgroundA role for microfluidic systems in precision medicine
Ayuso, J. M., Virumbrales-Muñoz, M., Lang, J. M., & Beebe, D. J. (2022) · Nature Communications · doi:10.1038/s41467-022-30384-7 · Cited by 216
Neufeld, L., Yeini, E., Reisman, N., Shtilerman, Y., Ben-Shushan, D., Pozzi, S., Madi, A., Tiram, G., Eldar-Boock, A., Ferber, S., et al. (2021) · Science Advances · doi:10.1126/sciadv.abi9119 · Cited by 189
Bioengineered 3D models of human pancreatic cancer recapitulate in vivo tumour biology
Osuna de la Peña, D., Trabulo, S. M. D., Collin, E., Liu, Y., Sharma, S., Tatari, M., Behrens, D., Erkan, M., Lawlor, R. T., Scarpa, A., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-25921-9 · Cited by 138
Tumor-on-chip modeling of organ-specific cancer and metastasis
Del Piccolo, N., Shirure, V. S., Bi, Y., Goedegebuure, S. P., Gholami, S., Hughes, C. C. W., Fields, R. C., & George, S. C. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.05.008 · Cited by 126
Applications of Microfluidics and Organ-on-a-Chip in Cancer Research
Regmi, S., Poudel, C., Adhikari, R., & Luo, K. Q. (2022) · Biosensors · doi:10.3390/bios12070459 · Cited by 143
Advancements in 3D Cell Culture Systems for Personalizing Anti-Cancer Therapies
Law, A. M. K., de la Fuente, L. R., Grundy, T. J., Fang, G., Valdés‐Mora, F., & Gallego‐Ortega, D. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.782766 · Cited by 119
Zhang, J., Tavakoli, H., Ma, L., Li, X., Han, L., & Li, X. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114365 · Cited by 114
Nanomedicine in Cancer Therapeutics: Current Perspectives from Bench to Bedside
Abdullah, K. M., Sharma, G., Singh, A. P., & Siddiqui, J. A. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02368-w · Cited by 135
“The use of tumor-on-a-chip and in vitro 3D models to mimic the complex tumor environment of human physiology is emerging as a promising solution to study the process of tumor penetration by nanodrugs in a more comprehensive manner [419–422].”
In vitro 3d cultures to model the tumor microenvironment
Fontana, F., Marzagalli, M., Sommariva, M., Gagliano, N., & Limonta, P. (2021) · Cancers · doi:10.3390/cancers13122970 · Cited by 103
“By maintaining the architecture of living tissues, these tools can be utilized to study the interplay between cancer cells and the surrounding stroma [30,31].”
BackgroundDadgar, N., Gonzalez-Suarez, A. M., Fattahi, P., Hou, X., Weroha, J. S., Gaspar-Maia, A., Stybayeva, G., & Revzin, A. (2020) · Microsystems & Nanoengineering · doi:10.1038/s41378-020-00201-6 · Cited by 99
High-Performance Nylon-6 Sustainable Filaments for Additive Manufacturing
Farina, I., Singh, N., Colangelo, F., Luciano, R., Bonazzi, G., & Fraternali, F. (2019) · Materials · doi:10.3390/ma12233955 · Cited by 93
A 3D View of Colorectal Cancer Models in Predicting Therapeutic Responses and Resistance
Reidy, E., Leonard, N. A., Treacy, O., & Ryan, A. E. (2021) · Cancers · doi:10.3390/cancers13020227 · Cited by 92
Experimental Models of Hepatocellular Carcinoma—A Preclinical Perspective
Blidișel, A., Marcovici, I., Coricovac, D. E., Huţ, E. F., Dehelean, C. A., & Cretu, O. M. (2021) · Cancers · doi:10.3390/cancers13153651 · Cited by 83
“In particular, tumor-on-a-chip models add a new dimension to the mimicry of the human cancer microenvironment, offering great promise for the cost-effective and high-throughput evaluation of antineoplastic drugs [108].”
BackgroundIn Vitro Glioblastoma Models: A Journey into the Third Dimension
Paolillo, M., Comincini, S., & Schinelli, S. (2021) · Cancers · doi:10.3390/cancers13102449 · Cited by 90
“This issue can be addressed by analyzing cells subtypes in vitro using innovative single cell multi‐omics techniques; indeed, several papers have re‐ ported single cells transcriptomic, genomic, and epigenomic analyses [131] whilst, despite some recent findings [132], single cell proteomic analysis is lagging behind i…”
BackgroundOrgan on Chip Technology to Model Cancer Growth and Metastasis
Imparato, G., Urciuolo, F., & Netti, P. A. (2022) · Bioengineering · doi:10.3390/bioengineering9010028 · Cited by 82
“Several COC models have been developed in the last years allowing one to manipulate the TME for studying cell behavior under specific metabolic gradients conditions [84] or to study the TME changes correlated to CAF interaction and vice versa [16,21,40,85,86].”
MethodBreast tumor-on-chip models: From disease modeling to personalized drug screening
Bano, S., Dahiya, U. R., Mishra, S., Ayache, J., Casquillas, G. V., Caballero, D., Reis, R. L., & Kundu, S. C. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.12.057 · Cited by 83
Microfluidic Systems for Cancer Diagnosis and Applications
Akgönüllü, S., Bakhshpour, M., Pişkin, A. K., & Denizli, A. (2021) · Micromachines · doi:10.3390/mi12111349 · Cited by 80
Modeling human tumor-immune environments in vivo for the preclinical assessment of immunotherapies
Bareham, B. R., Georgakopoulos, N., Matas‐Céspedes, A., Curran, M., & Saeb‐Parsy, K. (2021) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-021-02897-5 · Cited by 83
Emerging tumor-on-chips with electrochemical biosensors
Lei, L., Ma, B., Xu, C., & Liu, H. (2022) · TrAC Trends in Analytical Chemistry · doi:10.1016/j.trac.2022.116640 · Cited by 72
Pozzi, S., Scomparin, A., Dangoor, S. I., Ajamil, D. R., Ofek, P., Neufeld, L., Krivitsky, A., Vaskovich‐Koubi, D., Kleiner, R., Dey, P., et al. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.04.001 · Cited by 79
Shah, S., & D’Souza, G. G. M. (2025) · Cells · doi:10.3390/cells14100732 · Cited by 83
Engineered Vasculature for Organ-on-a-Chip Systems
Aazmi, A., Zhou, H., Li, Y., Yu, M., Xu, X., Wu, Y., Ma, L., Zhang, B., & Yang, H. (2021) · Engineering · doi:10.1016/j.eng.2021.06.020 · Cited by 69
Marrella, A., Fedi, A., Varani, G., Vaccari, I., Fato, M., Firpo, G., Guida, P., Aceto, N., & Scaglione, S. (2021) · PLoS ONE · doi:10.1371/journal.pone.0245536 · Cited by 70
Chen, L., Wei, X., Gu, D., Xu, Y., & Zhou, H. (2023) · Cancer Letters · doi:10.1016/j.canlet.2022.216048 · Cited by 61
Bridging the gap between tumor-on-chip and clinics: a systematic review of 15 years of studies
Bouquerel, C., Dubrova, A., Hofer, I., Phan, D. T. T., Bernheim, M., Ladaigue, S., Cavaniol, C., Maddalo, D., Cabel, L., Mechta-Grigoriou, F., et al. (2023) · Lab on a Chip · doi:10.1039/d3lc00531c · Cited by 58
Castro, F., Pereira, C. L., Macedo, M. H., Almeida, A., Silveira, M. J., Dias, S., Cardoso, A. P., Oliveira, M. J., & Sarmento, B. F. C. C. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.06.001 · Cited by 66
Computational Simulations in Advanced Microfluidic Devices: A Review
Carvalho, V. M., Rodrigues, R. O., Lima, R. A., & Teixeira, S. (2021) · Micromachines · doi:10.3390/mi12101149 · Cited by 66
Tumor-microenvironment-on-a-chip: the construction and application
Xu, H., Wen, J., Yang, J., Zhou, S., Li, Y., Xu, K., Li, W., & Li, S. (2024) · Cell Communication and Signaling · doi:10.1186/s12964-024-01884-4 · Cited by 65
“The true reproduction of the dynamics of the tumor microenvironment is considered to be a key factor in evaluating the accuracy and specificity of anticancer drugs [23].”
BackgroundOrganoids: A new approach in toxicity testing of nanotherapeutics
Nabi, S. U., Ali, S. I., Rather, M. A., Sheikh, W. M., Altaf, M., Singh, H., Mumtaz, P. T., Mishra, N. C., Nazir, S. U., & Bashir, S. M. (2021) · Journal of Applied Toxicology · doi:10.1002/jat.4206 · Cited by 47
“Consequently, frameworks for cell-to-cell interactions and cell-to-tissue interactions are mainly focused on tissue-on-a-chip platforms, and incredibly advanced organ-on-a-chip systems are being explored for NP profiling (Trujillo-de Santiago et al., 2019; Zervantonakis et al., 2012).”
BackgroundMicrofluidic technologies for immunotherapy studies on solid tumours
Paterson, K., Zanivan, S. R., Glasspool, R. M., Coffelt, S. B., & Zagnoni, M. (2021) · Lab on a Chip · doi:10.1039/d0lc01305f · Cited by 54
Cancer Models on Chip: Paving the Way to Large‐Scale Trial Applications
Gil, J. F., Moura, C. S., Silvério, V., Gonçalves, G., & Santos, H. A. (2023) · Advanced Materials · doi:10.1002/adma.202300692 · Cited by 49
Engineering Breast Cancer On-chip—Moving Toward Subtype Specific Models
Moccia, C., & Haase, K. (2021) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2021.694218 · Cited by 51
Al-Kabani, A., Huda, B., Haddad, J., Yousuf, M., Bhurka, F., Ajaz, F., Patnaik, R., Jannati, S., & Banerjee, Y. (2025) · Cancers · doi:10.3390/cancers17132163 · Cited by 56
Strategies Using Gelatin Microparticles for Regenerative Therapy and Drug Screening Applications
Nii, T. (2021) · Molecules · doi:10.3390/molecules26226795 · Cited by 47
Safhi, A. Y. (2022) · Pharmaceuticals · doi:10.3390/ph15060678 · Cited by 48
“In this condition, Cancer-on-a-chip is a microfluidic device that recreates tumor physiology and allows for a continuous supply of nutrients or therapeutic compounds [190].”
BackgroundScaffold-free generation of heterotypic cell spheroids using acoustofluidics
Wu, Z., Chen, B., Wu, Y., Xia, Y., Chen, H., Gong, Z., Hu, H., Ding, Z., & Guo, S. (2021) · Lab on a Chip · doi:10.1039/d1lc00496d · Cited by 40
Rapid Formation of Multicellular Spheroids in Boundary‐Driven Acoustic Microstreams
Rasouli, R., & Tabrizian, M. (2021) · Small · doi:10.1002/smll.202101931 · Cited by 42
Sztankovics, D., Moldvai, D., Petővári, G., Gelencsér, R., Krencz, I., Raffay, R. E., Dankó, T., & Sebestyén, A. R. (2023) · Pathology & Oncology Research · doi:10.3389/pore.2023.1610996 · Cited by 39
Ustun, M., Dabbagh, S. R., Ilci, I., Onder, T. B., & Taşoğlu, S. (2021) · Micromachines · doi:10.3390/mi12050490 · Cited by 43
“Real-time analysis Integration of biosensors to microfluidic chips [53,55] Detection of cell adhesion, separation, and migration Eliminating the need for time-consuming, large cell population-based experiments [53]”
BackgroundMethodKim, J. H., Lee, S., Kang, S. J., Choi, Y. W., Choi, S. Y., Park, J. Y., & Chang, I. H. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22168887 · Cited by 38
“Most cells in the body are exposed to interstitial fluid, and biomolecules secreted from the cells are transferred to the surroundings by diffusion rather than by the convection of body fluids [29].”
BackgroundEngineering hyaluronic acid-based cryogels for CD44-mediated breast tumor reconstruction
Rezaeeyazdi, M., Colombani, T., Eggermont, L. J., & Bencherif, S. A. (2022) · Materials Today Bio · doi:10.1016/j.mtbio.2022.100207 · Cited by 43
3D fluid-dynamic ovarian cancer model resembling systemic drug administration for efficacy assay
Marrella, A. (2020) · ALTEX · doi:10.14573/altex.2003131 · Cited by 36
“Recently, micro-fluidic systems (so called lab-on-chip) have been developed with the ambition to overcome some of these disadvantages (Trujillo-de Santiago et al., 2019).”
Background3D Tumor Spheroid Models for In Vitro Therapeutic Screening of Nanoparticles
Daunys, S., Janonienė, A., Januškevičienė, I., Paškevičiūtė, M., & Petrikaitė, V. (2021) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-58174-9_11 · Cited by 32
Kazerouni, A. S., Gadde, M., Gardner, A. L., Hormuth, D. A., Jarrett, A. M., Johnson, K. E., Lima, E. A. B. F., Lorenzo, G., Phillips, C. M., Brock, A., et al. (2020) · iScience · doi:10.1016/j.isci.2020.101807 · Cited by 39
“This strategy has been exploited to model angiogenesis and the motility of invasive cancer cells resulting from epithelial-to-mesenchymal transition (Deisboeck et al., 2011; Vilanova et al., 2017).”
BackgroundAffolter, A., Lammert, A., Kern, J., Scherl, C., & Rotter, N. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.666515 · Cited by 36
“In a recent review the application of tumor-on-chip systems in precision or personalized medicine is addressed (Trujillo-de Santiago et al., 2019).”
BackgroundBiomimetic Microfluidic Platforms for the Assessment of Breast Cancer Metastasis
Sigdel, I., Gupta, N. K., Faizee, F., Khare, V. M., Tiwari, A. K., & Tang, Y. (2021) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2021.633671 · Cited by 34
“…of existing in vivo models, recent research has shifted focus to the development of microfluidics-based devices to study the stepwise metastasis of breast cancers (Peela et al., 2017; Bray et al., 2019; Sontheimer-Phelps et al., 2019; Trujillo-de Santiago et al., 2019; Coughlin and Kamm, 2020).”
BackgroundHot or cold: Bioengineering immune contextures into in vitro patient-derived tumor models
Too, N. S. H., Ho, N. C. W., Adine, C., Iyer, N. G., & Fong, E. L. S. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.05.001 · Cited by 34
3D-bioprinted cholangiocarcinoma-on-a-chip model for evaluating drug responses
Liu, Q., Mille, L. S., Villalobos, C., Anaya, I., Vostatek, M., Yi, S., Li, W., Liao, J., Wu, H., Song, Y., et al. (2023) · Bio-Design and Manufacturing · doi:10.1007/s42242-022-00229-9 · Cited by 33
Self-citationKey aspects for conception and construction of co-culture models of tumor-stroma interactions
Mason, J. E., & Öhlund, D. (2023) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2023.1150764 · Cited by 32
“More complicated co-culture examples in microfluidic devices can be considered tumor-on-a-chip devices, although the distinction between a tumor-co-culture in a microfluidic setting and a tumoron-a-chip is blurred (Trujillo-de Santiago et al., 2019).”
BackgroundApplications of Polymers for Organ-on-Chip Technology in Urology
Gălățeanu, B., Hudiță, A., Bîru, E. I., Iovu, H., Zaharia, C., Simsensohn, E., Costache, M., Petca, R., & Jinga, V. (2022) · Polymers · doi:10.3390/polym14091668 · Cited by 32
Pagnotta, G., Kalia, S., Lisa, L. D., Cicero, A. F. G., Borghi, C., & Focarete, M. L. (2022) · Bioprinting · doi:10.1016/j.bprint.2022.e00218 · Cited by 34
Tumor‐On‐A‐Chip Models for Predicting In Vivo Nanoparticle Behavior
de Roode, K. E., Hashemi, K., Verdurmen, W. P. R., & Brock, R. E. (2024) · Small · doi:10.1002/smll.202402311 · Cited by 35
Engineering confining microenvironment for studying cancer metastasis
Jiang, K., Liang, L., & Lim, C. T. (2021) · iScience · doi:10.1016/j.isci.2021.102098 · Cited by 28
“…by changing the formula, chemical modification of the gels, high precision 3D bioprinting, and advanced imaging techniques that can visualize cell-ECM interaction at the subcellular level (Huang et al., 2014; Li and Kumacheva, 2018; Trujillo-de Santiago et al., 2019; Vasudevan et al., 2020).”
BackgroundTackling Current Biomedical Challenges With Frontier Biofabrication and Organ-On-A-Chip Technologies
Celikkin, N., Presutti, D., Maiullari, F., Fornetti, E., Agarwal, T., Paradiso, A., Volpi, M., Święszkowski, W., Bearzi, C., Barbetta, A., et al. (2021) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2021.732130 · Cited by 26
“As mentioned above, several in vitro organ and 3D tumor models have already been generated, and their deep characterizations are progressively implemented by emerging multi-omic technologies (Agarwal et al., 2017; Trujillo-de Santiago et al., 2019).”
BackgroundSelf-citationFabozzi, A., Sala, F. D., di Gennaro, M., Solimando, N., Pagliuca, M., & Borzacchiello, A. (2021) · Polymer Chemistry · doi:10.1039/d1py01077h · Cited by 27
Bioprinting and its Use in Tumor-On-A-Chip Technology for Cancer Drug Screening: A Review
Fang, L., Liu, Y., Qiu, J., & Wan, W. (2022) · International Journal of Bioprinting · doi:10.18063/ijb.v8i4.603 · Cited by 28
“These systems hold a lot of potential for low-cost, highthroughput anticancer drug screening[25-27].”
BackgroundWang, T., Green, R. J., Howell, M., Martinez, T. E., Dutta, R., Mohapatra, S., & Mohapatra, S. S. (2020) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2020.102294 · Cited by 27
Technological Advances in Tumor-On-Chip Technology: From Bench to Bedside
Bērziņa, S., Harrison, A., Taly, V., & Xiao, W. (2021) · Cancers · doi:10.3390/cancers13164192 · Cited by 29
“Several reviews have covered tumor-on-chip development [6,7], as well as the achievements of in vitro mimicry of the TME [1,8].”
BackgroundRecent advances in lung-on-a-chip technology for modeling respiratory disease
Negrete, J. A. T., Das, P., Najafikhoshnoo, S., Zanganeh, S., & Esfandyarpour, R. (2023) · Bio-Design and Manufacturing · doi:10.1007/s42242-023-00241-7 · Cited by 24
Self-citationSánchez-Salazar, M. G., Oliver, R. C.-L., Ramos-Meizoso, S., Jerezano-Flores, V. S., Gallegos-Martínez, S., Bolívar‐Monsalve, E. J., Ceballos‐González, C. F., Santiago, G. T., & Álvarez, M. M. (2023) · Bioengineering · doi:10.3390/bioengineering10050554 · Cited by 26
Self-citationDevices and techniques used to obtain and analyze three‐dimensional cell cultures
Agrawal, G., Ramesh, A., Aishwarya, P., Samson, J. S., & Ravi, M. (2021) · Biotechnology Progress · doi:10.1002/btpr.3126 · Cited by 29
“For example, the commonly used alginate hydrogel can be infused with electro-spun poly(lactide-co-glycolide) (PLGA) nanofibers using nano-in-micro (NIM) technology, which has been shown to enhance cell–cell and cell–matrix interactions.(13,14)”
MethodEvolution of Metastasis Study Models toward Metastasis‐On‐A‐Chip: The Ultimate Model?
Ruiz‐Espigares, J., Nieto, D., Moroni, L., Jiménez, G., & Marchal, J. A. (2021) · Small · doi:10.1002/smll.202006009 · Cited by 23
Flores-Torres, S., Jiang, T., Kort-Mascort, J., Yang, Y. K., Peza-Chavez, O., Pal, S., Mainolfi, A., Pardo, L. A., Ferri, L. E., Bertos, N., et al. (2023) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.2c00998 · Cited by 25
Mimicking and surpassing the xenograft model with cancer-on-chip technology
Komen, J., van Neerven, S. M., van den Berg, A., Vermeulen, L., & van der Meer, A. D. (2021) · EBioMedicine · doi:10.1016/j.ebiom.2021.103303 · Cited by 23
Cancer Stem Cells in Tumor Modeling: Challenges and Future Directions
Dogan, E., Kısım, A., Bati‐Ayaz, G., Kubicek, G. J., Pesen‐Okvur, D., & Miri, A. K. (2021) · Advanced NanoBiomed Research · doi:10.1002/anbr.202100017 · Cited by 25
3D Tumor Models for Breast Cancer: Whither We Are and What We Need
Balachander, G. M., Kotcherlakota, R., Nayak, B., Kedaria, D., Rangarajan, A., & Chatterjee, K. (2021) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.1c00230 · Cited by 23
Three-Dimensional Cell Culture Models of Hepatocellular Carcinoma — a Review
Ayvaz, I., Sunay, D., Sarıyar, E., Erdal, E., & Karagonlar, Z. F. (2021) · Journal of Gastrointestinal Cancer · doi:10.1007/s12029-021-00772-1 · Cited by 22
Prasad, S., Chandra, A., Cavo, M., Parasido, E., Fricke, S., Lee, Y., D’Amone, E., Gigli, G., Albanese, C., Rodriguez, O., et al. (2020) · Nanotechnology · doi:10.1088/1361-6528/abc208 · Cited by 30
A hitchhiker’s guide to cancer models
Budhwani, K. I., Patel, Z. H., Guenter, R. E., & Charania, A. A. (2022) · Trends in biotechnology · doi:10.1016/j.tibtech.2022.04.003 · Cited by 22
Nieto, D., Jiménez, G., Moroni, L., López‐Ruiz, E., Gálvez‐Martín, P., & Marchal, J. A. (2022) · Medicinal Research Reviews · doi:10.1002/med.21914 · Cited by 20
“The static culture condition associated with spheroid models does not recapitulate the in vivo conditions, including mechanical forces or dynamic flow, and so prevents long culture experiments which result in not precise drug toxicity and sensibility studies.(7) Three‐dimensional (3D) bioprinting is a rapidly expandin…”
BackgroundInterplay between the DNA Damage Response and Immunotherapy Response in Cancer
Lee, E. C. Y., Kok, J. S.-T., Teh, B. T., & Lim, K. S. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232113356 · Cited by 23
Kheiri, S., Chen, Z., Yakavets, I., Rakhshani, F., Young, E. W. K., & Kumacheva, E. (2023) · Biotechnology Journal · doi:10.1002/biot.202200621 · Cited by 21
Recent advances in cancer-on-a-chip tissue models to dissect the tumour microenvironment
Seaman, K., Sun, Y., & You, L. (2023) · Med-X · doi:10.1007/s44258-023-00011-1 · Cited by 26
“Such a platform would allow for the study of cancer biology and for the precise screening of novel anti-cancer drug candidates [20, 21, 25, 26].”
BackgroundInfluentialModelling Epithelial Ovarian Cancer in Mice: Classical and Emerging Approaches
Zakarya, R., Howell, V. M., & Colvin, E. K. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21134806 · Cited by 25
Mendoza-Martinez, A. K., Loessner, D., Mata, Á., & Azevedo, H. S. (2021) · Cancers · doi:10.3390/cancers13225745 · Cited by 21
Harnessing Tissue Engineering Tools to Interrogate Host-Microbiota Crosstalk in Cancer
Udayasuryan, B., Nguyen, T. T. D., Slade, D. J., & Verbridge, S. S. (2020) · iScience · doi:10.1016/j.isci.2020.101878 · Cited by 16
“While we refer the reader to several excellent review topics that go intomore depth (Cox et al., 2015;Ma et al., 2018; Shang et al., 2019; Trujillo-de Santiago et al., 2019; Tsai et al., 2017), here we will focus on some representative examples.”
BackgroundGallegos-Martínez, S., Buentello, D. C., Pérez-Álvarez, K. A., Lara-Mayorga, I. M., Aceves-Colin, A. E., Zhang, Y. S., Santiago, G. T., & Álvarez, M. M. (2024) · Biofabrication · doi:10.1088/1758-5090/ad5765 · Cited by 16
“ToCs have become an important resource in biomedical research [9, 11], and many relevant examples of their applications have been published recently [9, 10, 12, 14–17].”
Self-citationMicrofluidic-enabled self-organized tumor model for in vitro cytotoxicity assessment of doxorubicin
Yang, Y., Liu, S., Chen, C., Huang, H., Tao, L., Qian, Z., & Li, W. (2020) · Biomedical Microdevices · doi:10.1007/s10544-020-00523-2 · Cited by 16
“Microfluidic techniques have gained wide applicability for in vitro 3D cancer cell studies and drug evaluation (Han et al. 2016; Shang et al. 2019; Trujillo-de Santiago et al. 2019; Valente et al. 2017; Zhang et al. 2018).”
BackgroundEngineering stromal heterogeneity in cancer
Tang, L. J. W., Zaseela, A., Toh, C. C. M., Adine, C., Aydar, A. O., Iyer, N. G., & Fong, E. L. S. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.05.027 · Cited by 17
Nanodelivery Systems Face Challenges and Limitations in Bone Diseases Management
Giordano, F., Lenna, S., Rampado, R., Brozovich, A., Hirase, T., Tognon, M. G., Martini, F., Agostini, M., Yustein, J. T., & Taraballi, F. (2021) · Advanced Therapeutics · doi:10.1002/adtp.202100152 · Cited by 23
Wen, X., Takahashi, S., Hatakeyama, K., & Kamei, K. (2021) · Micromachines · doi:10.3390/mi12050550 · Cited by 16
“Microfluidic technology can also be applied for in vitro cancer diagnosis with very small amounts of cancer tissue from patient biopsy specimens, and to predict the efficacy and side effects of anti-cancer drugs [3,51,52].”
BackgroundNovel Ex Vivo Models of Epithelial Ovarian Cancer: The Future of Biomarker and Therapeutic Research
Clark, J., Fotopoulou, C., Cunnea, P., & Krell, J. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.837233 · Cited by 17
Can 3D bioprinting solve the mystery of senescence in cancer therapy?
Shboul, S. A., DeLuca, V. J., Dweiri, Y. M., & Saleh, T. (2022) · Ageing Research Reviews · doi:10.1016/j.arr.2022.101732 · Cited by 17
Human-derived Tumor-On-Chip model to study the heterogeneity of breast cancer tissue
Jeibouei, S., Monfared, A. K., Hojat, A., Aref, A. R., Shams, F., Dolati, M., Moradi, A., Hosseini, M., Javadi, S. M. R., Ajoudanian, M., et al. (2024) · Biomaterials Advances · doi:10.1016/j.bioadv.2024.213915 · Cited by 16
Bayona, C., Alza, L., Ranđelović, T., Sallan, M. C., Visa, A., Cantí, C., Ochoa, I., Oliván, S., & Herreros, J. (2024) · Cell Death and Disease · doi:10.1038/s41419-024-06492-1 · Cited by 19
Zhang, F., Jozani, K. A., Chakravarty, A., Lin, D. S. Y., Hollinger, A., Rajasekar, S., & Zhang, B. (2025) · Advanced Healthcare Materials · doi:10.1002/adhm.202402946 · Cited by 16
Gallegos-Martínez, S., Lara-Mayorga, I. M., Samandari, M., Mendoza-Buenrostro, C., Flores-Garza, B. G., Reyes‐Cortés, L. M., Segoviano-Ramírez, J. C., Zhang, Y. S., Santiago, G. T., & Álvarez, M. M. (2022) · Biofabrication · doi:10.1088/1758-5090/ac61a4 · Cited by 16
“Tumor-on-a-chip systems [37] have recently become an alternative to conducting the culture of spheroids under dynamic conditions for extended periods (i.”
Self-citationBaka, Z., Stiefel, M., Figarol, A., Godier, C., Mallick, A., Joubert, O., Ashammakhi, N. A., Gaffet, É., & Alem, H. (2022) · Progress in Biomedical Engineering · doi:10.1088/2516-1091/ac8259 · Cited by 15
“This is partly attributed to the lack of reliable preclinical models that can successfully reproduce in vivo drug responses [4], complex tumor micro-environment and cancer related pathophysiological events [5] such as cancer cell-stroma interactions, angiogenesis and metastasis.”
Capuana, E., Testa, M., Marco, C. D., Lopresti, F., & Carrubba, V. L. (2025) · Advanced Healthcare Materials · doi:10.1002/adhm.202500378 · Cited by 15
van der Merwe, L., Svitina, H. M., Willers, C., Wrzesinski, K., & Gouws, C. (2022) · Biotechnology Progress · doi:10.1002/btpr.3253 · Cited by 11
Integrative microphysiological tissue systems of cancer metastasis to the liver
Clark, A. M., Allbritton, N. L., & Wells, A. H. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.06.010 · Cited by 13
Tostado, C. P., Ong, L. X. D., Heng, J. W. J., Miccolis, C., Chia, S., Seow, J. J. W., Toh, Y., & DasGupta, R. (2024) · Bioengineering & Translational Medicine · doi:10.1002/btm2.10628 · Cited by 12
Bioengineered Liver Models for Investigating Disease Pathogenesis and Regenerative Medicine
Kukla, D. A., & Khetani, S. R. (2021) · Seminars in Liver Disease · doi:10.1055/s-0041-1731016 · Cited by 12
Considerations for modelling diffuse high-grade gliomas and developing clinically relevant therapies
Higginbottom, S. L., Tomaskovic‐Crook, E., & Crook, J. M. (2023) · Cancer and Metastasis Reviews · doi:10.1007/s10555-023-10100-7 · Cited by 14
Wang, W., Liu, Y., Huang, X., Liang, F., Luo, H., Mao, Z., Shi, J., Wang, L., Peng, J., & Chen, Y. (2024) · Talanta · doi:10.1016/j.talanta.2024.126473 · Cited by 11
Tumor Organoids: The Era of Personalized Medicine
Rassomakhina, N. V., Ryazanova, A. Y., Likhov, A. R., Bruskin, S. A., Maloshenok, L. G., & Zherdeva, V. V. (2024) · Biochemistry (Moscow) · doi:10.1134/s0006297924140086 · Cited by 14
“The tumor-on-chip devices are supplemented by 3D bi-oprinting, computational fluid dynamics, and “omics” technologies [146] that should facilitate the use of tumor organoids as a new platform for drug screening, identification of potential targets, and development of precision therapies [147].”
Shafran, Y., Deutsch, M., Afrimzon, E., Ravid-Hermesh, O., Sobolev, M., Eizig, Z. B.-O., Shainberg, A., & Zurgil, N. (2020) · Toxicology in Vitro · doi:10.1016/j.tiv.2020.105067 · Cited by 9
Parihar, P., Sunildutt, N., Rahim, C. S. A., Samantasinghar, A., Lim, J., & Choi, K. H. (2024) · Advanced Therapeutics · doi:10.1002/adtp.202300410 · Cited by 10
Metadata
- Authors
- Trujillo-de Santiago, G., Flores-Garza, B. G., Tavares-Negrete, J. A., Lara-Mayorga, I. M., González-Gamboa, I., Zhang, Y. S., Rojas-Martínez, A., Ortiz-López, R., & Álvarez, M. M.
- Affiliations
- Centro de Biotecnología-FEMSA, Tecnologico de Monterrey, Monterrey, Nuevo León CP 64849, Mexico
- Tecnológico de Monterrey (MX)
- Brigham and Women's Hospital (US)
- Centro de Investigación y Transferencia en Salud, Hospital San José, Tecnologico de Monterrey, Monterrey, Nuevo León CP 64849, Mexico
- Corresponding author
- Álvarez, Mario Moisés
- ORCID
- Venue
- Materials
- Publisher
- MDPI AG
- Published
- 2019-09-11
- Volume
- 12
- Issue
- 18
- Pages
- 2945
- ISSN
- 1996-1944 (ISSN-L)
- PMC
- PMC6766252
- OpenAlex
- W2972592345
- Cited by
- 184
- References
- 231
- Citations by year
- 2026: 12 · 2025: 17 · 2024: 47 · 2023: 21 · 2022: 25 · 2021: 47 · 2020: 13 · 2019: 2
- FWCI
- 1.76
- Type
- journal article
- Language
- en
- Open access
- gold
- dx.doi.org
- Licence
- Locations
- Materials (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Consejo Nacional de Ciencia y Tecnología (SNI256730, SNI 26048)
- Tecnologico de Monterrey (002EI CIN01)
- Topics
- Physical Sciences › Engineering › Biomedical Engineering › 3D Printing in Biomedical Research
- Physical Sciences › Engineering › Biomedical Engineering › Microfluidic and Capillary Electrophoresis Applications
- Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
- Keywords
- tumor-on-a-chip, microfluidics, solid tumors, tumor microenvironment, 3D tumor culture, anticancer drug screening, precision oncology, 3D bioprinting, computational fluid dynamics, high-throughput omics
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.